Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.51 |
| ▸ | CDC25A | P30304 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 6/20 | 0.50 |
| ▸ | HTR1A | P08908 | 4/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.50 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29643502 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CYP2D6CYP1A2CYP2C19MEN1 | |
| SCHEMBL591246 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CYP2D6CYP1A2CYP2C19MEN1 | |
| SCHEMBL27474717 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CYP2D6CYP1A2CYP2C19MEN1 | |
| SCHEMBL590887 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CYP2D6CYP1A2CYP2C19MEN1 | |
| SCHEMBL7708386 | 0.98 | HTR7 (0.51) | ALDH1A1CYP2D6CYP1A2CYP2C19MEN1 | |
| SCHEMBL19656193 | 0.93 | CHRM2 (0.54) | ALDH1A1CYP2D6CYP1A2CYP2C19MEN1 | |
| SCHEMBL29725098 | 0.91 | HTR2A (0.58) | ALDH1A1CYP2D6CYP1A2MEN1KMT2A | |
| SCHEMBL1110826 | 0.91 | HTR2A (0.58) | ALDH1A1CYP2D6CYP1A2MEN1KMT2A | |
| SCHEMBL12307238 | 0.89 | HTR2A (0.64) | ALDH1A1CYP2D6CYP1A2CYP2C19MEN1 | |
| SCHEMBL12307218 | 0.89 | HTR2A (0.64) | ALDH1A1CYP2D6CYP1A2CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144078-A1 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | SYMERES NETHERLANDS B.V. (NL) | 2025-05-08 | — | — | US | claimed |
| US-20250011316-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2025-01-09 | — | — | US | claimed |
| EP-4479390-A2 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS Oncology, LLC (US) | 2024-12-25 | — | — | EP | claimed |
| CN-116908158-A | Drug mitochondrial toxicity detection method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-10-20 | — | — | CN | claimed |
| WO-2023158679-A2 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS ONCOLOGY, LLC (US) | 2023-08-24 | — | — | WO | claimed |
| US-11672810-B2 | Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer | LUNELLA BIOTECH, INC. (CA) | 2023-06-13 | — | — | US | claimed |
| US-20220249438-A1 | CARBOCYANINE COMPOUNDS FOR TARGETING MITOCHONDRIA AND ERADICATING CANCER STEM CELLS | LUNELLA BIOTECH, INC. (CA) | 2022-08-11 | — | — | US | claimed |
| US-20220202836-A1 | THERAPEUTICS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER | LUNELLA BIOTECH, INC. (CA) | 2022-06-30 | — | — | US | claimed |
| EP-3989963-A1 | CARBOCYANINE COMPOUNDS FOR TARGETING MITOCHONDRIA AND ERADICATING CANCER STEM CELLS | Lunella Biotech, Inc. (CA) | 2022-05-04 | — | — | EP | claimed |
| CN-114173773-A | Carbocyanine compounds for targeting mitochondria and eradicating cancer stem cells | 卢内拉生物技术有限公司 | 2022-03-11 | — | — | CN | claimed |
| EP-3897659-A1 | TRIPLE COMBINATION THERAPIES FOR ANTI-AGING | Lunella Biotech, Inc. (CA) | 2021-10-27 | — | — | EP | claimed |
| EP-3897658-A1 | TRIPLE COMBINATION THERAPIES FOR TARGETING MITOCHONDRIA AND KILLING CANCER STEM CELLS | Lunella Biotech, Inc. (CA) | 2021-10-27 | — | — | EP | claimed |
| CN-113453690-A | Triple therapy for anti-aging | 卢内拉生物技术有限公司 | 2021-09-28 | — | — | CN | claimed |
| CN-113164504-A | Azithromycin and roxithromycin derivatives as antiageing agents | 卢内拉生物技术有限公司 | 2021-07-23 | — | — | CN | claimed |
| US-20210215702-A1 | BIOMARKERS AND THERAPEUTICS FOR ENDOCRINE THERAPY RESISTANCE | LUNELLA BIOTECH, INC. (CA) | 2021-07-15 | — | — | US | claimed |
| US-20210137925-A1 | TARGETING MITOCHONDRIAL FISSION THROUGH MDIVI-1 DERIVATIVES | LUNELLA BIOTECH, INC. (CA) | 2021-05-13 | — | — | US | claimed |
| WO-2020264246-A1 | CARBOCYANINE COMPOUNDS FOR TARGETING MITOCHONDRIA AND ERADICATING CANCER STEM CELLS | LUNELLA BIOTECH, INC. (CA) | 2020-12-30 | — | — | WO | claimed |
| WO-2020242857-A1 | THERAPEUTICS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER | LUNELLA BIOTECH, INC. (CA) | 2020-12-03 | — | — | WO | claimed |
| WO-2020131696-A1 | TRIPLE COMBINATION THERAPIES FOR TARGETING MITOCHONDRIA AND KILLING CANCER STEM CELLS | LUNELLA BIOTECH, INC. (CA) | 2020-06-25 | — | — | WO | claimed |
| WO-2020131704-A1 | TRIPLE COMBINATION THERAPIES FOR ANTI-AGING | LUNELLA BIOTECH, INC. (CA) | 2020-06-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137925-A1 | TARGETING MITOCHONDRIAL FISSION THROUGH MDIVI-1 DERIVATIVES | FIS1, DNM1L, MFN2 | ALDH1A1 1412/4885CYP2D6 2226/4885CYP1A2 4032/4885 |
| US-11672810-B2 | Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer | CYP27B1, TFAM, FIS1 | ALDH1A1 2193/4885CYP2D6 381/4885CYP1A2 1059/4885 |
| US-20220249438-A1 | CARBOCYANINE COMPOUNDS FOR TARGETING MITOCHONDRIA AND ERADICATING CANCER STEM CELLS | UQCRC1, MT-CO2, UQCRC2 | ALDH1A1 414/4885CYP2D6 650/4885CYP1A2 826/4885 |
| US-20210215702-A1 | BIOMARKERS AND THERAPEUTICS FOR ENDOCRINE THERAPY RESISTANCE | TFAM, TUFM, RARS2 | ALDH1A1 3860/4885CYP2D6 3833/4885CYP1A2 3755/4885 |
| US-20220202836-A1 | THERAPEUTICS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER | CYP27B1, TFAM, FIS1 | ALDH1A1 2193/4885CYP2D6 381/4885CYP1A2 1059/4885 |
| US-20250011316-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX2, PRDX6 | ALDH1A1 331/4885CYP2D6 1422/4885CYP1A2 996/4885 |
| US-20250144078-A1 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | TYMS, TOP1, TOP2A | ALDH1A1 1562/4885CYP2D6 1569/4885CYP1A2 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.